• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

    10/8/24 8:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email

    Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health.

    KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion.

    Organon Canada logo (CNW Group/Organon Canada Inc.)

    Effective September 1, 2024, Jeffrey Malawski has been appointed to the position of Executive Director, Women's Health and Established Brands. Previously, Mr. Malawski led the Corporate Affairs and Community Engagement business unit at Organon Canada, a position now held by Geneviève Gauthier whose promotion came into effect on October 1, 2024. Prior to this role, Ms. Gauthier served as Associate Director, Policy & Access, and was instrumental in enhancing the company's corporate presence at both federal and provincial levels.

    "Geneviève and Jeff have played key roles since our company was founded in 2021 and have helped to create Organon these last three years. Their experience in the industry, expertise, and commitment to Organon and women's health will help us achieve our company's growth for the future," said Michael Casia, President and Managing Director, Organon Canada. "These leadership changes reflect our commitment to fostering a high-performance culture while ensuring we continue to meet the unmet health needs in women and the needs of our community.

    Since the establishment of Organon Canada, Mr. Malawski has been responsible for shaping and leading the development of policies, pricing and contracting strategies, implementing the Patient Support Programs, as well as overseeing the company's communications activities. Throughout his tenure, Mr. Malawski has played a pivotal role in the success of Organon Canada, its culture and values, and in ensuring the success of his talented team.

    "I look forward to continuing on my adventure at Organon Canada and to contributing to the business unit's continued success to help tackle the unmet health needs of women in Canada," said Jeffrey Malawski. "I am proud of this talented team that drives innovation and delivers impactful solutions to improve the health and well-being of women. Collectively, we will build on our successes and strive to make a lasting difference for girls, women and their communities."

    With over 20 years of experience in the healthcare industry, Geneviève Gauthier brings a wealth of expertise in market research, sales, marketing, public health, and policy and access. Recognized for her strategic mindset, collaborative approach, and authenticity, Ms. Gauthier will play a key role in overseeing the company's communication and community engagement activities, ensuring that its Patient Support Programs deliver exceptional value to both patients and healthcare professionals, while also helping to shape policy and contracting strategies that align with the company's organizational objectives. In addition, she has been an important driving force of the company's mission and social impact strategy, notably through the meaningful relationship she has cultivated with Le Chaînon, one of the largest resources for women in difficulty in Québec, truly bringing our values to life.

    "I am honoured to be part of the Organon Canada leadership team that launched our company's operations in Canada as a standalone entity. Building awareness and fostering collaborations to address women's unmet health needs and creating a stronger healthcare system for all will be an extremely rewarding journey," said Geneviève Gauthier. "I look forward to continuing our efforts working alongside like-minded organizations and building on the solid strides our team has made."

    Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a particular focus on women. The company is also a proud recipient of the Women in Governance Parity Certification.

    Mr. Malawski holds an M.Sc. and B.Sc. in Health Administration from both the University of Wisconsin and University of Minnesota. Read Jeffrey Malawski's biography here.

    Ms. Gauthier holds an MBA in Marketing from Simon Fraser University and a Bachelor's degree in Business Administration from Université du Québec à Montréal. You can read her biography here.

    About Organon

    Organon is an independent global healthcare company with a strategy to help improve the health of women throughout their lives. Organon's diverse portfolio offers more than 60 medicines and products in women's health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon's current products, the company invests in innovative solutions and research to drive future growth opportunities in women's health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.

    Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

    For more information, visit www.organon.ca and connect with us on LinkedIn.

    SOURCE Organon Canada Inc.

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/08/c6345.html

    Get the next $OGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    10/14/2022$27.00 → $25.00Neutral → Underperform
    BofA Securities
    9/6/2022$37.00 → $34.00Neutral → Overweight
    Piper Sandler
    8/5/2022$40.00 → $37.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/13/24 5:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/5/24 3:47:19 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      1/25/24 12:23:52 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Leadership Updates

    Live Leadership Updates

    See more

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OGN
    SEC Filings

    See more

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

      Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

      3/10/25 12:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

      Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk

      10/8/24 8:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP, Corp. Dev. Karp Daniel bought $28,828 worth of shares (3,500 units at $8.24), increasing direct ownership by 8% to 46,669 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:09:34 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Organon & Co.

      10-Q - Organon & Co. (0001821825) (Filer)

      5/2/25 8:42:12 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Organon & Co. (0001821825) (Filer)

      5/1/25 7:12:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Organon & Co.

      DEFA14A - Organon & Co. (0001821825) (Filer)

      4/25/25 4:40:13 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by Evercore ISI

      Evercore ISI downgraded Organon from Outperform to In-line

      5/2/25 8:13:50 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by JP Morgan with a new price target

      JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously

      9/6/24 7:47:49 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by Goldman with a new price target

      Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously

      11/3/23 7:22:32 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP, Corp. Dev. Karp Daniel bought $28,828 worth of shares (3,500 units at $8.24), increasing direct ownership by 8% to 46,669 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:09:34 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Financials

    Live finance-specific insights

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

      Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

      4/1/25 7:30:00 AM ET
      $BIIB
      $OGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations